Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The efficacy of single agent liposomal doxorubicin as compared to single agent docetaxel will
be evaluated as first line treatment in metastatic breast cancer patients, with subsequent
crossover to the opposite arm at disease progression or patient intolerance. We will explore
this as well as any possible cross resistance between these two agents.